This study aims to identify recurrent genetic alterations in relapsed or refractory (RR) naturalkiller/T-cell lymphoma (NKTL) patients who have achieved complete response (CR) with programmed cell death 1 (PD-1) blockade therapy. Seven of the eleven patients treated with pembrolizumab achieved CR while the remaining four had progressive disease (PD). Using whole genome sequencing (WGS), we found recurrent clonal structural rearrangements (SR) of the PD-L1 gene in four of the seven (57%) CR patients' pretreated tumors. These PD-L1
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Introduction Natural-killer/T cell lymphoma (NKTL) is an uncommon and aggressive malignancy with a predilection for Asian, Mexican and South American populations (1) . With the exception of Japan, it is the most common mature T-cell lymphoma in Asia (2) . Neoplastic cells are invariably infected by the Epstein Barr virus (EBV) and are characterized by a cytotoxic phenotype (3) .
In recent years, immune checkpoint (ICP) inhibitors have shown promising objective response rates (ORR) in the treatment of many malignancies (4) . Of note, the most impressive result is 80% ORR from the use of programmed death-1 (PD-1 or CD279) inhibitors in relapsed or refractory (RR) Hodgkin lymphoma (HL) (5, 6) . Currently, clinical studies involving non-small-cell lung carcinoma, melanoma and bladder cancer have generally concluded that immunohistochemistry (IHC) positivity of programmed death-ligand 1 (PD-L1) coincides with greater likelihood of response to PD-1/PD-L1 blockade. Intriguingly, there was also a lower but definite response rate in patients with PD-L1-negative tumors (7) . These observations suggest that more information could be harnessed from the tumors and augment the current de facto criteria of selecting patients for PD-1 blockade therapy (8, 9) .
With the major advancements in sequencing technologies, recurring somatic mutations altering the JAK-STAT pathway, epigenetic modifiers, DDX3X gene and germline genetic predisposition in the HLA-DPB1 gene have been found in NKTL patients but none of these studies have investigated these tumors using whole genome sequencing (WGS) techniques (10) (11) (12) (13) (14) (15) (16) . In order to explore the NKTL genome for actionable alterations associated to PD-1 blockade therapy, we employed WGS data to study the somatic alterations of 11 pretreated NKTL tumors that have corresponding clinical response data to pembrolizumab treatment.
Results

Exceptional response to pembrolizumab in relapsed or refractory NKTL patients
Eleven NKTL patients from Singapore, China and Hong Kong who were relapsed or refractory (RR) to L-asparaginase containing chemotherapy regimens, after a median of two (range: 1-5) lines of treatments, were included into this study (Table 1) . These 11 pembrolizumab-treated patients had a median age of 42 years old at diagnosis (range: 27-66 years) and a median follow-up of 11 months (range: 2-25 months) since treated with pembrolizumab. Sixty-four percent (7 of 11 cases) of the patients achieved complete responses (CR) while 36% (4 of 11 cases) of the patients had progressive disease (PD). Two patients (NKTL26 & NKTL31) remained in remission from pembrolizumab for more than two years, which is rare in RR NKTL (17) . The most recent pembrolizumab-treated case (NKTL28) also achieved ongoing remission for at least 6 months. The median duration of response to pembrolizumab (for responding patients) was 14 months.
PD-L1 positivity could not stratify response to pembrolizumab in NKTL patients
To verify if PD-L1 positivity in NKTL tumors could predict response to pembrolizumab, we proceeded to determine the positivity of PD-L1 in all 11 pretreated NKTL tumors using IHC.
The same pathologist assessed PD-L1 positivity in all the tumors in this study to ensure consistency ( Table 2 ). The PD-L1 positivity in the tumor cells varied greatly in both patients who achieved CR and PD. PD-L1 positivity in the pretreated tumors of the patients with CR ranged from 6% to 100% while the PD-L1 staining intensity among patients with PD ranged from 35% to 90%. Hence PD-L1 staining intensity could not differentiate between patients who achieved CR and those who had PD. Interestingly, NKTL29 had only 6% of tumor cells stained positive for PD-L1 but achieved CR from pembrolizumab. Apart from this PD-L1 low CR case, all four PD cases were strongly stained for PD-L1, with an average of 69% (range: 50% -90%) tumor cells stained positively for PD-L1. This is concordant with clinical trials reporting that antitumor activity from PD-1 blockade therapy was also observed in melanoma and non small-cell lung carcinoma patients with low baseline PD-L1 positivity (18, 19) . Our current study shows that some patients with low PD-L1 positivity may have good responses to PD-1 blockade.
Whole genome sequencing and analysis of 11 RR NKTL pembrolizumab-treated patients
To identify genomic biomarkers of response to PD-1 blockade therapy in NKTL, whole genome sequencing was performed on pairs of tumor-normal samples obtained from 11 patients who were subsequently treated with pembrolizumab. The NKTL tumors and, whole blood or buccal swabs, were sequenced to an average depth of 66.6x and 37.5x, respectively (Supplementary Table 1 ). Somatic variant calling yielded an average of 1.15 single nucleotide variants (SNVs) and microIndels per Mb for each paired sample. An average of 39 (range: 1 - Table 2 ) somatic non-silent protein-coding variants per sample was identified and is comparable to previous reports on whole-exome sequencing of fresh-frozen NKTL samples (range: 41-42) (10, 11) . In total, we found 10 genes to be recurrently mutated ( Supplementary Fig. 1 ). Among them, only PD-L1 structural rearrangement (SR) and JAK3activating mutations (p.A573V) were recurrent and mutually exclusive to one another among the initial tumors of patients who achieved CR. Furthermore, PD-L1 SR is the most frequent somatic alteration identified in four of seven (57%) initial tumors of patients who achieved CR ( Fig. 1A) . These PD-L1 SRs consist of inter-chromosomal translocations (NKTL28 & NKTL31), tandem duplication (NKTL26) and micro-inversion (NKTL1) that disrupted the 3'UTR of PD-L1 (Fig. 1B) . In NKTL28 and NKTL31, exon 7 of PD-L1 was translocated to 2q24.2 and intron 6 of PD-L1 was translocated to 6p12.2, respectively ( Supplementary Fig.   2 ). In NKTL26, the right breakpoint of tandem duplication was located within the 3'UTR of PD-L1 and the left breakpoint was validated to be ~32kbp upstream. This duplication event yielded a copy of 3'UTR-disrupted and wild type copy of PD-L1 ( Supplementary Fig. 3 ). The final PD-L1 SR in NKTL1 consists of a 206 bp micro-inversion that sits entirely within the 3'UTR of PD-L1. These somatic alterations were absent in the initial tumors from the four patients who had PD with pembrolizumab.
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Besides sequence analysis by our established genomic pipeline, visual inspection was also performed for known recurrent mutated genes of NKTL to avoid artefacts (10-13, 16, 20, 21) .
Among frequently mutated genes in NKTL, TP53 stopgain (p.W14X) and STAT3 missense (p.H410R) were also found in NKTL27 and NKTL28, respectively. Mutations in genes associated with antigen presentation and interferon gamma pathways, which are known to associate resistance to immune checkpoint blockade in melanoma (22) , are not found in our cohort.
Regulatory activity of PD-L1 3'UTR in NKTL
All four novel PD-L1 SRs were predicted to lose whole or part of the PD-L1 3'UTR, except the micro-inversion that spanned across 206 bp and sits entirely within the 3'UTR of PD-L1.
To determine the functional significance of this micro-inversion in regulating PD-L1 expression, the wild type and mutant (with 206 bp inversion) PD-L1 3'UTR were cloned into a luciferase reporter assay system and transfected into lymphoma and leukemia cell lines, namely, NK-S1, K-562 and Jurkat ( Fig. 2A ). Our results show that the wild type PD-L1
3'UTR could effectively suppress the luciferase activity of the reporter protein and the identified micro-inversion could relieve this suppression in NK-S1, K-562 and Jurkat cell lines (P = 0.01, P = 0.01 and P = 0.03, two-tailed t-test; Fig. 2B ). Indeed, we have observed moderate to high levels (range: 20%-100%) of PD-L1 positivity in these four tumors harboring PD-L1 3'UTR SR ( Table 2) . These results offer a direct explanation to how these NKTL tumors would have evaded immune surveillance by upregulating PD-L1 expression.
PD-L1 structural rearrangements and JAK3-activating mutations are clonal in NKTL
Although the mechanisms of response to PD-1 blockade from PD-L1 3'UTR SRs and JAK3activating mutations remain to be elucidated, we wanted to investigate if the clonality of these alterations could support the CR in patients who had PD-L1 and JAK3 alterations in their pretreated tumors, from the single-agent regime of pembrolizumab. From the somatic variants called, we were able to obtain solutions for the clonal architectures of 10 cases (SciClone (23) did not have a clonality solution for NKTL1). Five cases, four CR cases and one PD cases, had a clonal architecture ( Table 3 and Supplementary Fig. 4 ). The somatic PD-L1 and JAK3 alterations identified in this study resided in the founding clone of their corresponding pretreated tumors. Given these results, the clonality analysis does support the extent of response in our patients who achieved CR from the single-agent regime of pembrolizumab therapy.
Discussion
Immunotherapy, in particular PD-1 blockade therapy, has shown promise in the treatment of several cancers, including NKTL. Recent study on adult T cell lymphoma (ATLL) has uncovered recurrent disruptions to the 3'UTR of PD-L1 that induce tumor immune evasion via aberrant expression of PD-L1 (24) . However, the study did not have concurrent clinical response data to further associate PD-L1 3'UTR SR and response to pembrolizumab. In our study, we showed that four out of seven (57%) who achieved CR to PD-1 blockade had clonal PD-L1 3'UTR SR and demonstrated that the SR could disrupt the suppression function of wild type PD-L1 3'UTR. PD-L1 3'UTR SR was also recently identified in a single case of ovarian cancer where the patient achieved CR with pembrolizumab (25) , further supporting its role as a potential biomarker of response to PD-1 blockade therapy in NKTL.
All NKTLs are diagnostically EBER+ and the EBV protein, LMP1 could constitutively upregulate PD-L1 (26) . It is reasonable to speculate that NKTLs will respond to PD-1 inhibitors as they are innately PD-L1+. Indeed, all seven RR-NKTL patients in our previous clinical study had an initial response to pembrolizumab (27) . However, at the time of this writing, three of the seven patients have progressed and died of disease. We did not find alterations of the PD-L1 and JAK3 genes in these PD cases. Conceivably, this initial "pseudoremission" could be attributed by exogenous factors, such as EBV upregulating PD-L1 that was transiently blocked by initial dosages of pembrolizumab. Hence, high PD-L1 positivity in tumors will not necessarily equate to good response to PD-1 blockade. In addition, the PD-L1 IHC scores also varied greatly (6%, 2+ to 100%, 3+) within our cohort, and both NKTL25 and NKTL27 had PD despite having high PD-L1 staining grade for their pretreated tumors, questioning the effectiveness of PD-L1 positivity alone as a biomarker of response to PD-1 blockade in NKTL.
Interestingly, no rearrangements were identified within the PD-L2 gene and PD-L1 always served as the 5' rearrangement partner. This is in contrast to other hematologic malignancies where the over-expression of PD-L1 and/or PD-L2 is achieved by diverse mechanisms such as genomic amplification, JAK2 or PD-L2 translocations ( Supplementary Table 3 ) (24, 28, 29) . This suggests that different tumors have evolved alternate mechanisms for immune evasion.
The presence of recurrent JAK3-activating mutations in our CR cases also coincides with a recent report showing the long-term benefit of PD-1 blockade in a single lung cancer patient with JAK3-activating mutations (30) . Moreover, Zaretsky et al recently reported that loss of JAK1, JAK2 or B2M, leading to a lack of response to interferon gamma or antigen presentation confers resistance to pembrolizumab in metastatic melanoma (22) . These data led us to speculate that JAK3-activating mutations could play an important role in patient's response to immune checkpoint inhibitors and the mechanisms require further investigation.
The initial tumor from one of our CR patients (ID: NKTL43), both PD-L1 WT and JAK3 WT , harbored a 3 bp insertion in the ARID1B gene ( Supplementary Fig. 5 ). A recent study has reported PBRM1-deficient and ARID2-deficient tumors correlated with better response to anti-PD-1/PD-L1 therapy renal cell carcinoma (31) . There seems to be a relationship between truncating alterations in the subunits of the SWI/SNF complex and response to PD-1/PD-L1 therapy. However, the mechanisms and which members of these large complexes are involved in conferring response to immune checkpoint blockade therapy await further investigation.
To the best of our knowledge, this is the first study to report on the correlates of genomic features with response to PD-1 blockade therapy in NKTL using WGS data. The main limitation of this study is the small sample size and this is mainly due to the rarity of NKTL and also that PD-1 blockade is still not approved for the treatment of RR NKTL. In summary, PD-1 blockade in NKTL is promising and genomic correlates of response from our study will have to be further validated in larger cohorts of NKTL patients treated with immune checkpoint therapy.
Materials and Methods
Patients and study setup
Our study cohort consists of 11 patients with RR NKTL who had failed L-asparaginase-based chemotherapy regimens from Singapore, China and Hong Kong. NKTL1, NKTL25, NKTL26, NKTL43, NKTL44 and NKTL45 were never sequenced before and were included from our previous study (27) . 
Genomic DNA extraction
Genomic DNA from snap frozen and formalin-fixed paraffin-embedded (FFPE) tumor tissues, and whole blood was extracted as previously described (32) . Buccal swab genomic DNA was purified using E.Z.N.A. Tissue DNA Kit (Omega Bio-tek) according to manufacturer's instructions. The quality and quantity were assessed as described elsewhere (32) . All sequenced cases in our study, except NKTL25 being a snap frozen sample, were FFPE samples.
Whole genome sequencing
Whole-genome sequencing (WGS) was performed for all 11 pairs of tumor-normal samples described in this study. All sequencing libraries were prepared using TruSeq Nano DNA Library Prep Kit (Illumina). Due to high fragmentation of genomic DNA from FFPE material, a size selection step was conducted prior to library preparation for the FFPE tumor samples.
Amplifiable DNA fragments of ~200 bp from our FFPE samples are used for sequencing library construction to avoid false-negatives confidently in our discovery for SR within the PD-L1 gene. The gDNA from the FFPE tumors were sequenced on the HiSeq4000 System (Illumina) with a 2x150 bp format and the gDNA for the matching normals were sequenced on the HiSeq X System (Illumina) with a 2x150 bp format.
Detection and filtering of structural rearrangements
Sequencing reads were aligned using BWA-MEM (33) to the hs37d5 human reference genome. Strelka2 (34) and MuSE (35) were used to detect somatic short variants. Variants were subsequently annotated by wAnnovar (36) on 7 th August 2018. The genic regions of PD-L1 and PD-L2 were manually inspected for somatic structural rearrangements with IGV.
Read pairs were marked as discordant if they did not align to the reference genome with the expected orientation and/or within the expected insert size. Reads were flagged as clipped when either end of the read did not match the reference genome. Strelka2 was run with default WGS profile. MUSE was run with default parameters.
Analysis of tumor clonality
SciClone (23) was used to analyze the clonality architecture of the tumors. CANVAS (37) was used to analyze copy number and loss of heterozygousity information for each tumor, which were used as input for the clonality analysis by SciClone.
PCR and Sanger sequencing
Details about PCR conditions and sequencing are described elsewhere (38) . Primers were designed using Primer3 software (39) and the sequences are listed in Supplementary Table 4 .
Sanger sequences were aligned to human reference genome and confirmed with BLAT (40) .
Histological studies and scoring
PD-L1 IHC analysis was performed with anti-PD-L1 rabbit monoclonal antibody (SP263, Ventana) by Dr Jabed Iqbal. PD-L1 positivity was evaluated as a percentage of positively stained tumor cells at the cell membrane.
Cell lines and constructs
K-562 and Jurkat cell line was purchased from ATCC and NK-S1 (41) was generated inhouse.
LGC Standards authenticated the K-562 and Jurkat cell lines on 6 th October 2017.
Jurkat cells were maintained in RPMI 1640 (Gibco) supplemented with 10% FBS (HyClone), and K-562 and NK-S1 were grown in DMEM (Gibco) supplemented with 10% FBS (HyClone), 10% horse serum (Gibco) and 2 mM L-glutamine (Gibco). The cells were grown at 37 o C in the presence of 5% CO 2 and routinely checked for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit (Lonza).
Wild type PD-L1 3'UTR (ENST00000381573.8) from SNK6 cell line (generously provided by Dr. Norio Shimuzu) was cloned into the XhoI and NotI sites of the psiCHECK-2 vector (Promega). For the partially inverted 3'UTR recapitulating the rearrangement identified in sample NKTL1, three individual pieces with overhangs were amplified from a wild type sample (SNK6) and ligated together by PCR. Cloning was performed using Q5 High-Fidelity 2X Master Mix (New England BioLabs). All cloning primers used to clone the full-length wild type and mutant PD-L1 3'UTR are described in Supplementary Table 5 .
Transfection and luciferase assay
For K-562 and Jurkat, 5x10 4 cells and 6x10 4 cells were seeded on a 48-well plate in triplicates, respectively, and transfected with 250 ng plasmid DNA using the Lipofectamine 3000 Reagent (Invitrogen). For NK-S1 cells, 2x10 5 cells were electroporated in triplicates on a 24-well plate with 1 µg plasmid DNA using the Neon Transfection System (Invitrogen).
The pulse parameters used were the following: voltage 1300, width 10 and no. 3.
The cells were lysed with Passive Lysis Buffer (Promega) after 48 hours. Luminescence was measured using the Dual-Luciferase Reporter Assay System (Promega) and the GloMax-Multi+ Detection System (Promega). Renilla luciferase activities were divided by Firefly luciferase activities and the results were normalized to the empty vector control (mock).
Statistical significance was calculated by two-sided t-test. Statistical significance was considered as P<0.05. All experiments were repeated at least twice.
Data availability
The WGS data of 11 ENKL-normal/blood pairs have been deposited in European Genomephenome Archive (EGA) under the study accession code: EGAS00001002420. Supplementary Fig. 1 . Recurrent somatic mutated genes in the 11 pembrolizumab-treated patients' initial tumors. Supplementary Fig. 2 . Validation of PD-L1 rearrangements and JAK3-activating identified in Natural-Killer/T-Cell Lymphoma patients with complete response to pembrolizumab. Supplementary Fig. 3 . Schematics of the tandem duplication disrupting the 3'UTR of PD-L1 in NKTL26 inferred from whole genome sequencing data. Supplementary Fig. 4 . Clonality cluster plots from SciClone. Supplementary Fig. 5 . Validation of the 3bp insertion in ARID1B Identified in a Natural-Killer/T-Cell Lymphoma patient with complete response to pembrolizumab. Supplementary Table 1 . Statistics of the whole-genome sequencing data in our study. Supplementary Table 2 . Predicted non-silent protein-coding mutations. Supplementary Table 3 . PD-L1 and PD-L2 alterations described in hematological malignancies. Supplementary Table 4 . Primer-pairs used for the validation of PD-L1 structural rearrangement, JAK3-activating and ARID1B mutations. Table 2 . Membraneous PD-L1 immunohistochemical staining grade, PD-L1 H-score and PD-L1 positivity cells in the pretreated NKTL tumors of our study cohort. 
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